PaoloCaimiMD

Oncology • Cleveland, OH

Hematologic Oncology

Associate Professor / Cleveland Clinic

Join to view full profile

Dr. Caimi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Caimi's full profile

Already have an account?

Office
9500 Euclid Ave
CA6
Cleveland, OH 44106
Phone+1 216-445-4635

Fax+1 216-444-9464

Education & Training

Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Sinai Hospital of BaltimoreChief Residency, Internal Medicine, 2006 - 2007
Sinai Hospital of BaltimoreResidency, Internal Medicine, 2004 - 2006
Sinai Hospital of BaltimoreInternship, Internal Medicine, 2003 - 2004
Pontificia Universidad Catolica de ChileClass of 2002

Certifications & Licensure

OH State Medical License 2007 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Nov 01
Terminated
Phase 1
Double Cord Versus Haploidentical (BMT CTN 1101) Start of enrollment: 2012 Jun 01
Completed
Phase 3
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2011 May 01
Completed
Phase 1
Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2013 Apr 30
Completed
Phase 1
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma Start of enrollment: 2015 Jan 28
Completed
Phase 1, Phase 2
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2014 Nov 05
Completed
Phase 1
Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.
Available
T Cell Therapy of Opportunistic Cytomegalovirus Infection Start of enrollment: 2020 May 27
Recruiting
Early Phase 1
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Jun 26
Active, not recruiting
Phase 1, Phase 2
AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma Start of enrollment: 2018 Jul 09
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.
Mehdi Hamadani, Paolo F Caimi, Brian Hess, John Radford, Melhem Solh
Future Oncology. 2024-11-12
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
Narendranath Epperla, Ying Huang, Amanda F Cashen, John L Vaughn, Walter Hanel
Blood Advances. 2024-11-12
Understanding how CD19 expression levels impact the response to loncastuximab tesirine: a plain language summary.
Paolo F Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie
Future Oncology. 2024-11-07

Abstracts/Posters

Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preclinical Studies and Phase I Trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach By Targeting TGF-_ S...
Paolo Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction
Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay
Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Tr...
Paolo F Caimi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Preclinical Studies and a Phase I Trial of the TGF-β Receptor Inhibitor, Vactosertib (TEW-7197), in Combination with Pomalidomide in Patients with Multiple Myeloma Ref...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comparison of Pegfilgrastim and Filgrastim to Prevent Neutropenic Fever during Consolidation with High Dose Cytarabine for Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Direction of KIR Ligand Incompatibility Is Associated with Graft Failure and May Predict the Dominant Donor Following Double Umbilical Cord Blood Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Maintenance Therapy on Nature of First Relapse in Multiple Myeloma Patients Underwent Autologous Stem Cell Transplant
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients with Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

New Cellular and Immunotherapy Service Provides Patients with Standard of Care and Clinical Trial Opportunities for Novel TherapiesAugust 30th, 2024
ADC Therapeutics Announces Abstracts to Be Presented at the 63rd ASH Annual MeetingNovember 4th, 2021
"CAR-T Initiatives at UH" by Paolo Caimi, MDMarch 3rd, 2020
Join now to see all